[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353429-105":59,"doc-detail-353429-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","therapeutic-gfral-silencing-via-antisense-oligonucleotides-ameliorates-cancer-associated-cachexia-and-extends-survival-in-tumor-bearing-mice","Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice","","Cancer cachexia is a life-threatening wasting syndrome driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL, and effective central-targeted interventions remain limited. The study develops a potent GFRAL-targeting antisense oligonucleotide (Gfral-ASO, A427) that silences central Gfral expression in mice. In severe orthotopic tumor models, a single intracerebroventricular dose blunts GFRAL expression, reduces pathogenic neuronal activation, reverses muscle and adipose wasting, and significantly extends survival, outperforming systemic anti-GDF15 antibody for muscle functional rescue.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-gfral-silencing-via-antisense-oligonucleotides-ameliorates-cancer-associated-cachexia-and-extends-survival-in-tumor-bearing-mice/353429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-gfral-silencing-via-antisense-oligonucleotides-ameliorates-cancer-associated-cachexia-and-extends-survival-in-tumor-bearing-mice/353429.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic strategy does the study test for cancer cachexia?","Question",{"text":113,"@type":114},"The study develops an antisense oligonucleotide (Gfral-ASO, A427) to silence the central nervous system expression of Gfral, antagonizing GFRAL signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is the ASO administered and what central effects are observed?",{"text":118,"@type":114},"A single intracerebroventricular administration markedly blunts GFRAL expression and reduces pathogenic c-Fos neuronal activation in the area postrema and nucleus tractus solitarius.",{"name":120,"@type":111,"acceptedAnswer":121},"Does central Gfral silencing improve survival in tumor-bearing mice?",{"text":122,"@type":114},"Yes. Silencing central GFRAL signaling profoundly extends survival in tumor-bearing mice, while also reversing cachectic phenotypes such as muscle and adipose wasting.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353429,1790187088,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice  \nAuthors  \nHyun Jung Hong, Min Hee Lee, Minsung Park, ..., Ho Min Kim, Jinkuk Kim, Minho Shong  \nCorrespondence  \n[jinkuk@kaist.ac.kr](jinkuk@kaist.ac.kr) (J.K.),  \n[minhos@kaist.ac.kr](minhos@kaist.ac.kr) (M.S.)  \nIn brief  \nHong et al. demonstrate that silencing central GFRAL using an antisense oligonucleotide (ASO) reverses cancerassociated cachexia. In severe tumor models, a single central administration of the ASO mitigates muscle and adipose wasting, improves functional strength, and profoundly extends survival, highlighting receptor-targeted ASO therapy as a promising cachexia intervention.  \n• Gfral silencing reverses tumor-induced muscle and adipose tissue wasting  \n• ASO therapy offers superior muscle function rescue versus anti-GDF15 antibodies  \n• A single central dose of Gfral ASO significantly extends overall survival  \nHong et al., 2026, Cell Reports Medicine 7, 102939  \nAugust 18, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102939](https://doi.org/10.1016/j.xcrm.2026.102939)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice  \nHyun Jung Hong,1,7 Min Hee Lee,2,7 Minsung Park,1,7 Jung Tae Kim,1 Jaehun Kim,1 Sang-Hyeon Ju,1 Ju Hee Lee,3 Jong-Woo Sohn,4 Koeun Shong,5 Daiki Setoyama,6 Ho Min Kim,4 Jinkuk Kim,1,* and Minho Shong1,2,8,*  \n1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea  \n2THOR Therapeutics Inc. , A203, 40, Geumto-ro 80beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do 13453, Republic of Korea  \n3Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea  \n4Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea  \n5Center for Biomolecular & Cellular Structure, IBS, 55, Expo-ro, Yuseong-gu, Daejeon 34126, Republic of Korea  \n6Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan  \n7These authors contributed equally  \n8Lead contact  \n*Correspondence: [jinkuk@kaist.ac.kr](jinkuk@kaist.ac.kr) (J. K.), [minhos@kaist.ac.kr](minhos@kaist.ac.kr) (M.S.) [https://doi.org/10.1016/j.xcrm.2026.102939](https://doi.org/10.1016/j.xcrm.2026.102939)  \nSUMMARY  \nCancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO, A427) that specifically silences Gfral expression in the central nervous system. Using orthotopic mouse models of severe colon (MC38) and pancreatic (KPC and MPC1) cancers, we showthat a single intracerebroventricular administration of Gfral ASO markedly blunts GFRAL expression and pathogenic c-Fos neuronal activation in the area postrema and nucleus tractus solitarius. This central blockade reverses cachectic phenotypes, restoring body weight, muscle mass, and adipose depots. Notably, Gfral ASO achieves superior restoration of muscle (grip) strength compared with systemic anti-GDF15 neutralizing antibody. Crucially, silencing central GFRAL signaling profoundly extends survival of tumor-bearing mice. Our findings highlight central GFRAL antagonism via ASO as a promising therapeutic strategy for cancer cachexia.  \nINTRODUCTION  \nCancer-associated cachexia (CAC) is a multifactorial and debilitating wasting syndrome characterized by progressive loss of systemic energy reserves, primarily manifested through i","cbCaikJcO4LfU2Tm","https://ap.wps.com/l/cbCaikJcO4LfU2Tm","pdf",13532142,22,"English","# Summary\n# Introduction\n## Cancer-associated cachexia and clinical impact\n## GDF15-GFRAL signaling pathway\n## Rationale for central receptor targeting with ASOs","[{\"question\":\"What therapeutic strategy does the study test for cancer cachexia?\",\"answer\":\"The study develops an antisense oligonucleotide (Gfral-ASO, A427) to silence the central nervous system expression of Gfral, antagonizing GFRAL signaling.\"},{\"question\":\"How is the ASO administered and what central effects are observed?\",\"answer\":\"A single intracerebroventricular administration markedly blunts GFRAL expression and reduces pathogenic c-Fos neuronal activation in the area postrema and nucleus tractus solitarius.\"},{\"question\":\"Does central Gfral silencing improve survival in tumor-bearing mice?\",\"answer\":\"Yes. Silencing central GFRAL signaling profoundly extends survival in tumor-bearing mice, while also reversing cachectic phenotypes such as muscle and adipose wasting.\"}]","Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice | PDF",1790105334,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/615804a1788ed0c3f26d2b3fe9893ec8.webp",983,1276,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42477ef0b68e99c6f7ea155f27165720.webp",982,1275,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fe38b8b4e6b8cd6ebc8bdea777f932d.webp",981,1273,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cf754a2697eabbc4b76a0a8eebd2616.webp",980,1272]